MTA2 Antibody #15793
Filter:
- WB
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 75 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
MTA2 Antibody recognizes endogenous levels of total MTA2 protein. This antibody does not cross-react with other MTA proteins. This antibody detects a 50 kDa band of unknown origin in rat cell lysates.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro602 of human MTA2 protein. Antibodies are purified by peptide affinity chromatography.
Background
MTA2 is a component of the NuRD deacetylase complex, which is recruited by MBD3 and modulates the enzymatic activity of the histone deacetylase core (1,2). MTA2 is highly related to MTA1, but both proteins exist in biologically distinct complexes, with MTA2 being associated with complexes containing Sin3a and CHD4 (3) MTA2 has been shown to bind ERα and repress its activity and contributes to estradiol- and tamoxifen-resistant breast cancers (4). Indeed, the MTA proteins are critical regulators of many biological functions in both cancer and non-cancer settings (5,6). MTA2 upregulation has been reported in a multitude of cancers, including hepatocellular carcinomas, colorectal cancers, gastric cancers, and esophageal cancers (7-10). MTA2 has also been described in B cell development, where it interacts with Aiolos and Ikaros to control target genes (11).
- Zhang, Y. et al. (1999) Genes Dev 13, 1924-35.
- Saito, M. and Ishikawa, F. (2002) J Biol Chem 277, 35434-9.
- Yao, Y.L. and Yang, W.M. (2003) J Biol Chem 278, 42560-8.
- Cui, Y. et al. (2006) Mol Endocrinol 20, 2020-35.
- Sen, N. et al. (2014) Cancer Metastasis Rev 33, 869-77.
- Kumar, R. and Wang, R.A. (2016) Gene 582, 112-21.
- Shi, W. et al. (2015) Int J Clin Exp Pathol 8, 13083-9.
- Ding, W. et al. (2015) Int J Clin Exp Pathol 8, 7173-80.
- Zhou, C. et al. (2013) Mol Cancer 12, 102.
- Liu, Y.P. et al. (2012) Exp Ther Med 3, 745-749.
- Lu, X. et al. (2019) Cell Rep 28, 472-485.e5.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.